Enhanced antiproliferative effect of nitric oxide in cultured smooth muscle cells from diabetic rats

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 1, 1996, Pages 140-146

  Etienne, Pascale ^a   Parés Herbuté, Nuria ^a   Monnier, Louis ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Diabetes; Nitric oxide; Proliferation; Vascular smooth muscle cells

Indexed keywords

NITRIC OXIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG EFFECT; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; CELL DIVISION; CYCLIC GMP; DNA; L-LACTATE DEHYDROGENASE; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITROPRUSSIDE; RATS; RATS, WISTAR; VASODILATOR AGENTS;

EID: 0030058816     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199601000-00022     Document Type: Article

References (40)

1. Steiner G. Diabetes and atherosclerosis: metabolic links. Drugs 1988;36(suppl 3):22-6.
2. Kannel WB, Me Gee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1978;241:2035-8.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
4. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care 1992;15: 1156-67.
5. Chamley-Campbell JH, Campbell GR, Ross R. Phenotype-dependent response of cultured aortic smooth muscle serum mitogen. J Cell Biol 1981;89:379-83.
6. Newby AC, Southgate KM, Assender JW. Inhibition of vascular smooth muscle cell proliferation by endothelium-dependent vasodilators. Hertz 1992;17:291-9.
7. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
8. Myers PR, Minor RL, Guerra R, Bates JN, Harrison DG. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature 1990;345:161-3.
9. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
10. Ignarro L, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9.
11. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051-64.
12. Moncada S, Palmer RMJ. Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-4:.
13. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989;65:1-21.
14. Larson DM, Handenschild CC. Activation of smooth muscle cell outgrowth from BB/Wor rat aortas. Diabetes 1988;37: 1380-5.
15. Alipui C, Tenner TE, Ramos K. Rabbit aortic smooth muscle cell culture: a model for the pharmacological study of diabetes-induced alterations in cell proliferation. J Pharmacol Methods 1991;26:211-22.
16. Alipui C, Ramosk K, Tenner TE. Alterations of rabbit aortic smooth muscle cell proliferation in diabetes mellitus. Cardiovasc Res 1993;27:1229-32.
17. Kawano M, Koshikawa T, Kanzaki T, Morisaki N, Saito Y, Yoshida S. Diabetes mellitus induces accelerated growth of aortic smooth muscle cells: association with overexpression of PDGFβ-receptors. Eur J Clin Invest 1993;23:84-90.
18. Kamata K, Miyata N, Kasuya Y. Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J Pharmacol 1989;97:614-8.
19. Tomlinson KC, Gardiner SM, Hebden RA, Bennett T. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 1992;44:103-50.
20. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510-6.
21. Oyama Y, Kawasaki H, Hattori Y, Kanno M. Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur J Pharmacol 1986;131:75-8.
22. Wang YX, Brooks DP, Edwards RM. Attenuated glomerular cGMP production and renal vasodilation in streptozotocin-induced diabetic rats. Am J Physiol 1993;264:R952-6.
23. Harris KH, MacLeod KM. Influence of the endothelium on contractile responses of arteries from diabetic rats. Eur J Pharmacol 1988;153:55-64.
24. Mulhern M, Docherty JR. Effects of experimental diabetes on the responsiveness of rat aorta. Br J Pharmacol 1989;97: 1007-12.
25. Kawaluk EA, Seth P, Fung H-L. Metabolic activation of sodium nitroprusside to nitric oxide in vascular smooth muscle. J Pharmacol Exp Ther 1992;262:916-22.
26. Bodin P, Richard S, Travo C, et al. Responses of subcultured rat aortic smooth myocytes to vasoactive agents and KCL-induced depolarization. Am J Physiol 1991;260: C151-8.
27. Murad F, Mittal CK, Arnold WP, Katsuki S, Kimura H. Guanylate cyclase: activation by azide, nitro compounds, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Adv Cyclic Nucleotide Res 1978;9:145-58.
28. Martin W, Villani CM, Jothianandan D, Furchgott RF. Selective blockage of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther 1985; 232:708-16.
29. Garg UC, Hassid A. Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am J Physiol 1989;257: F60-6.
30. Feelisch M. The biological pathways of nitric oxide formation from nitrisovasodilators: appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solution. J Cardiovasc Pharmacol 1991;17 (suppl 3):S25-33.
31. Vilcek J, Pallombella VJ, Henriksem-De Stefano D, et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 1986;163:632-43.
32. Yang W, Ando J, Korenaga R, Toyo-oka T, Kamina A. Exogenous nitric oxide inhibits proliferation of cultured vascular endothelial cells. Biochem Biophys Res Commun 1994; 203:1160-7.
33. Miller MAW, Morgan RJ, Thompson CS, Mikhailidis DP, Jeremy JY. Adenylate and guanylate cyclase activity in the penis and aorta of the diabetic rat: an in vitro study. Br J Urol 1994;74:106-11.
34. Durante W, Sen AK, Sunahara FA. Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats. Br J Pharmacol 1988;94:463-8.
35. Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. J Clin Invest 1992;90:1110-5.
36. Brownlee MA, Cerami A, Vlassara H. Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-21.
37. Morel DW, Chisolm GM. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J Lipid Res 1989;30:1827-34.
38. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992;89:10-8.
39. Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanism in atherosclerosis. Arteriosclerosis 1989;9:567-78.
40. Libby P. Inflammatory and immune mechanisms in athero-genesis. Atherosclerosis Rev 1990;21:79-89.